Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1232 participants.
Also called NCT06742216
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,232 participants
- Registry
-
NCT06742216
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06742216. Randomized; quadruple masking; primary purpose treatment. Start 2020-11-03 (actual); primary completion 2023-08-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Monosialoganglioside
- Intervention (Drug)
- Placebo
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct06742216- Content hash
376f8be21d17f767b4857d1e00396c9afe160bb0a8d9409e388390bfcd6718ce